Symbols / PRAX Stock $335.61 +4.68% Praxis Precision Medicines, Inc.

Healthcare • Biotechnology • United States • NMS
PRAX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Marcio Silva De'Souza M.B.A.
Exch · Country NMS · United States
Market Cap 9.36B
Enterprise Value 8.57B
Income -326.53M
Sales —
FCF (ttm) -176.03M
Book/sh 50.61
Cash/sh 28.23
Employees 168
Insider 10d —
IPO Oct 16, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -34.07
PEG —
P/S —
P/B 6.63
P/C —
EV/EBITDA -24.00
EV/Sales —
Quick Ratio 15.66
Current Ratio 15.88
Debt/Eq 0.10
LT Debt/Eq —
EPS (ttm) -13.37
EPS next Y -9.85
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-07
Earnings (prior) 2026-05-07
ROA -23.04%
ROE -35.32%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 27.88M
Shs Float 24.01M
Insider Own 0.32%
Instit Own 115.78%
Short Float 13.58%
Short Ratio 9.27
Short Interest 3.78M
52W High 358.76
vs 52W High -6.45%
52W Low 35.21
vs 52W Low 853.17%
Beta 2.78
Impl. Vol. 0.78%
Rel Volume 0.66
Avg Volume 404.24K
Volume 265.56K
Target (mean) $652.18
Tgt Median $554.00
Tgt Low $166.00
Tgt High $1,245.00
# Analysts 17
Recom Strong_buy
Prev Close $320.61
Price $335.61
Change 4.68%
About

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE. In addition, the company is developing product candidates in pre-clinical trial comprising PRAX-020 to treat KCNT1; PRAX-080 that targets PCDH19 mosaic expression disorders; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a cooperation and license agreement with RogCon Inc.; and a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc. The company was formerly known as EpiPM Therapeutics, Inc. and changed its name to Praxis Precision Medicines, Inc. in October 2016. Praxis Precision Medicines, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$652.18
Mean price target
2. Current target
$335.61
Latest analyst target
3. DCF / Fair value
$-113.65
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$335.61
Low
$166.00
High
$1245.00
Mean
$652.18

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-20 reit BTIG Buy → Buy $843
2026-05-13 main Truist Securities Buy → Buy $715
2026-05-08 main Wedbush Underperform → Underperform $166
2026-05-08 reit BTIG Buy → Buy $843
2026-04-14 reit Needham Buy → Buy $510
2026-04-07 reit HC Wainwright & Co. Buy → Buy $1245
2026-04-06 reit BTIG Buy → Buy $843
2026-02-24 init Wolfe Research — → Outperform $500
2026-02-20 main Wells Fargo Equal-Weight → Equal-Weight $305
2026-02-20 main Baird Outperform → Outperform $433
2026-02-20 main Truist Securities Buy → Buy $700
2026-02-20 main Wedbush Underperform → Underperform $130
2026-02-10 main Guggenheim Buy → Buy $800
2026-02-04 main Needham Buy → Buy $510
2026-02-02 init Wells Fargo — → Equal-Weight $282
2026-01-30 main HC Wainwright & Co. Buy → Buy $1245
2026-01-28 main Piper Sandler Overweight → Overweight $1200
2026-01-12 main Wedbush Underperform → Underperform $95
2025-12-29 main BTIG Buy → Buy $843
2025-12-15 main Oppenheimer Outperform → Outperform $750
News
RSS: Latest PRAX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-06 KINDLER JEFFREY B Director — 1,166 $0.00 $0
2026-02-06 ARBUCKLE STUART A Director — 1,166 $0.00 $0
2026-01-08 SOUZA MARCIO SILVA DE Chief Executive Officer — 27,640 $0.00 $0
2026-01-08 SNIECINSKI MEGAN Chief Operating Officer — 9,625 $0.00 $0
2026-01-08 MASTROCOLA LAUREN Officer — 3,750 $0.00 $0
2026-01-08 NEMIROFF ALEX General Counsel — 6,875 $0.00 $0
2026-01-08 KELLY TIMOTHY EDWIN Chief Financial Officer — 8,800 $0.00 $0
2025-12-30 SOUZA MARCIO SILVA DE Chief Executive Officer — 400 $0.00 $0
2025-11-20 MASTROCOLA LAUREN Officer — 13,600 $43.37 $831,257
2025-11-20 NEMIROFF ALEX General Counsel — 25,130 $44.40 $1,853,531
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
-100.00%
8.55
+249.53%
2.45
0.00
Operating Revenue
0.00
-100.00%
8.55
+249.53%
2.45
0.00
Operating Expense
326.20
+56.29%
208.72
+62.02%
128.82
-40.08%
214.99
Research And Development
267.12
+75.26%
152.41
+75.66%
86.77
-44.04%
155.04
Selling General And Administration
59.08
+4.93%
56.30
+33.89%
42.05
-29.85%
59.95
General And Administrative Expense
59.08
+4.93%
56.30
+33.89%
42.05
-29.85%
59.95
Other Gand A
59.08
+4.93%
56.30
+33.89%
42.05
-29.85%
59.95
Total Expenses
326.20
+56.29%
208.72
+62.02%
128.82
-40.08%
214.99
Operating Income
-326.20
-62.96%
-200.16
-58.39%
-126.37
+41.22%
-214.99
Total Operating Income As Reported
-326.20
-62.96%
-200.16
-58.39%
-126.37
+41.22%
-214.99
EBITDA
-326.06
-63.19%
-199.81
-58.65%
-125.94
+41.30%
-214.57
Normalized EBITDA
-326.06
-63.19%
-199.81
-58.65%
-125.94
+41.30%
-214.57
Reconciled Depreciation
0.14
-60.89%
0.36
-17.13%
0.43
+3.10%
0.42
EBIT
-326.20
-62.96%
-200.16
-58.39%
-126.37
+41.22%
-214.99
Net Income
-303.27
-65.88%
-182.82
-48.30%
-123.28
+42.40%
-214.03
Pretax Income
-303.27
-65.88%
-182.82
-48.30%
-123.28
+42.40%
-214.03
Other Income Expense
22.93
+32.19%
17.35
+460.27%
3.10
+223.51%
0.96
Other Non Operating Income Expenses
22.93
+32.19%
17.35
+460.27%
3.10
+223.51%
0.96
Tax Provision
—
—
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-303.27
-65.88%
-182.82
-48.30%
-123.28
+42.40%
-214.03
Net Income From Continuing Operation Net Minority Interest
-303.27
-65.88%
-182.82
-48.30%
-123.28
+42.40%
-214.03
Net Income From Continuing And Discontinued Operation
-303.27
-65.88%
-182.82
-48.30%
-123.28
+42.40%
-214.03
Net Income Continuous Operations
-303.27
-65.88%
-182.82
-48.30%
-123.28
+42.40%
-214.03
Normalized Income
-303.27
-65.88%
-182.82
-48.30%
-123.28
+42.40%
-214.03
Net Income Common Stockholders
-303.27
-65.88%
-182.82
-48.30%
-123.28
+42.40%
-214.03
Otherunder Preferred Stock Dividend
—
—
—
—
Diluted EPS
—
-10.21
+45.37%
-18.69
+73.15%
-69.60
Basic EPS
—
-10.21
+45.37%
-18.69
+73.15%
-69.60
Basic Average Shares
—
17.91
+171.55%
6.59
+114.58%
3.07
Diluted Average Shares
—
17.91
+171.55%
6.59
+114.58%
3.07
Diluted NI Availto Com Stockholders
-303.27
-65.88%
-182.82
-48.30%
-123.28
+42.40%
-214.03
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
937.91
+94.14%
483.11
+449.31%
87.95
-23.61%
115.13
Current Assets
610.91
+51.08%
404.37
+376.40%
84.88
-23.42%
110.84
Cash Cash Equivalents And Short Term Investments
599.33
+52.67%
392.57
+382.86%
81.30
-19.10%
100.49
Cash And Cash Equivalents
357.33
+65.91%
215.37
+164.91%
81.30
+31.95%
61.62
Other Short Term Investments
242.00
+36.57%
177.19
0.00
-100.00%
38.87
Prepaid Assets
—
—
—
10.35
Other Current Assets
11.58
-1.91%
11.80
+229.75%
3.58
-65.41%
10.35
Total Non Current Assets
327.00
+315.30%
78.74
+2466.43%
3.07
-28.45%
4.29
Net PPE
0.24
-82.44%
1.36
-48.68%
2.65
-31.51%
3.87
Gross PPE
1.74
-36.09%
2.72
-25.51%
3.66
-17.71%
4.44
Accumulated Depreciation
-1.50
-10.20%
-1.36
-35.62%
-1.00
-75.70%
-0.57
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
0.09
-91.87%
1.13
-45.20%
2.06
-28.85%
2.90
Machinery Furniture Equipment
1.23
+0.00%
1.23
+0.00%
1.23
+0.00%
1.23
Other Properties
0.41
+15.60%
0.36
+0.00%
0.36
+16.18%
0.31
Investments And Advances
326.76
+324.57%
76.96
0.00
—
Other Non Current Assets
—
0.42
+0.00%
0.42
+0.00%
0.42
Total Liabilities Net Minority Interest
59.77
+58.71%
37.66
+106.03%
18.28
-53.16%
39.02
Current Liabilities
59.77
+59.18%
37.55
+138.43%
15.75
-54.14%
34.34
Payables And Accrued Expenses
40.95
+52.08%
26.93
+182.98%
9.52
-65.67%
27.72
Payables
24.63
+96.58%
12.53
+115.44%
5.82
-60.37%
14.67
Accounts Payable
24.63
+96.58%
12.53
+115.44%
5.82
-60.37%
14.67
Current Accrued Expenses
16.32
+13.35%
14.40
+289.14%
3.70
-71.64%
13.05
Pensionand Other Post Retirement Benefit Plans Current
18.71
+99.82%
9.37
+152.02%
3.72
+32.57%
2.80
Current Debt And Capital Lease Obligation
0.11
-91.26%
1.26
+11.81%
1.13
+12.04%
1.00
Current Capital Lease Obligation
0.11
-91.26%
1.26
+11.81%
1.13
+12.04%
1.00
Current Deferred Liabilities
—
0.00
-100.00%
1.39
-50.60%
2.82
Current Deferred Revenue
—
0.00
-100.00%
1.39
-50.60%
2.82
Total Non Current Liabilities Net Minority Interest
0.00
-100.00%
0.11
-95.65%
2.53
-45.91%
4.68
Long Term Debt And Capital Lease Obligation
0.00
-100.00%
0.11
-91.96%
1.37
-45.13%
2.50
Long Term Capital Lease Obligation
0.00
-100.00%
0.11
-91.96%
1.37
-45.13%
2.50
Non Current Deferred Liabilities
—
0.00
-100.00%
1.16
-46.79%
2.18
Non Current Deferred Revenue
—
0.00
-100.00%
1.16
-46.79%
2.18
Stockholders Equity
878.14
+97.13%
445.45
+539.38%
69.67
-8.46%
76.11
Common Stock Equity
878.14
+97.13%
445.45
+539.38%
69.67
-8.46%
76.11
Capital Stock
0.01
+7.14%
0.01
+7.69%
0.01
+160.00%
0.01
Common Stock
0.01
+7.14%
0.01
+7.69%
0.01
+160.00%
0.01
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
25.20
+29.72%
19.42
+120.91%
8.79
+167.05%
3.29
Ordinary Shares Number
25.20
+29.72%
19.42
+120.91%
8.79
+167.05%
3.29
Additional Paid In Capital
2,017.57
+57.44%
1,281.52
+77.11%
723.58
+19.22%
606.92
Retained Earnings
-1,140.01
-36.24%
-836.74
-27.96%
-653.92
-23.23%
-530.64
Gains Losses Not Affecting Retained Earnings
0.56
-13.91%
0.65
0.00
+100.00%
-0.17
Other Equity Adjustments
0.56
-13.91%
0.65
—
-0.17
Total Equity Gross Minority Interest
878.14
+97.13%
445.45
+539.38%
69.67
-8.46%
76.11
Total Capitalization
878.14
+97.13%
445.45
+539.38%
69.67
-8.46%
76.11
Working Capital
551.14
+50.25%
366.82
+430.62%
69.13
-9.63%
76.50
Invested Capital
878.14
+97.13%
445.45
+539.38%
69.67
-8.46%
76.11
Total Debt
0.11
-91.96%
1.37
-45.13%
2.50
-28.71%
3.50
Capital Lease Obligations
0.11
-91.96%
1.37
-45.13%
2.50
-28.71%
3.50
Net Tangible Assets
878.14
+97.13%
445.45
+539.38%
69.67
-8.46%
76.11
Tangible Book Value
878.14
+97.13%
445.45
+539.38%
69.67
-8.46%
76.11
Available For Sale Securities
326.76
+324.57%
76.96
—
—
Investmentin Financial Assets
326.76
+324.57%
76.96
0.00
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-249.07
-89.04%
-131.76
-18.55%
-111.14
+39.94%
-185.04
Cash Flow From Continuing Operating Activities
-249.07
-89.04%
-131.76
-18.55%
-111.14
+39.94%
-185.04
Net Income From Continuing Operations
-303.27
-65.88%
-182.82
-48.30%
-123.28
+42.40%
-214.03
Depreciation Amortization Depletion
0.14
-60.89%
0.36
-17.13%
0.43
+3.10%
0.42
Depreciation
0.14
-60.89%
0.36
-17.13%
0.43
+3.10%
0.42
Depreciation And Amortization
0.14
-60.89%
0.36
-17.13%
0.43
+3.10%
0.42
Other Non Cash Items
1.03
-69.91%
3.43
+310.16%
0.84
+11.30%
0.75
Stock Based Compensation
33.94
-17.94%
41.36
+66.39%
24.86
-13.07%
28.59
Change In Working Capital
22.68
+107.65%
10.92
+177.83%
-14.03
-687.87%
-1.78
Change In Prepaid Assets
0.64
+107.78%
-8.22
-221.46%
6.77
+1138.03%
0.55
Change In Payables And Accrued Expense
23.30
+2.08%
22.82
+231.53%
-17.35
-163.99%
-6.57
Change In Accrued Expense
11.20
-30.48%
16.11
+289.60%
-8.50
+18.81%
-10.46
Change In Payable
12.10
+80.20%
6.71
+175.81%
-8.86
-327.52%
3.89
Change In Account Payable
12.10
+80.20%
6.71
+175.81%
-8.86
-327.52%
3.89
Change In Other Working Capital
—
-2.55
-4.25%
-2.45
-148.40%
5.06
Change In Other Current Liabilities
-1.26
-11.81%
-1.13
-12.04%
-1.00
-23.92%
-0.81
Investing Cash Flow
-311.15
-25.21%
-248.49
-737.98%
38.95
-59.80%
96.89
Cash Flow From Continuing Investing Activities
-311.15
-25.21%
-248.49
-737.98%
38.95
-59.80%
96.89
Net PPE Purchase And Sale
-0.06
0.00
+100.00%
-0.05
+88.74%
-0.44
Purchase Of PPE
-0.06
0.00
+100.00%
-0.05
+88.74%
-0.44
Capital Expenditure
-0.06
—
-0.05
+88.74%
-0.44
Net Investment Purchase And Sale
-311.09
-25.19%
-248.49
-737.16%
39.00
-59.93%
97.33
Purchase Of Investment
-623.81
-67.91%
-371.52
0.00
+100.00%
-83.02
Sale Of Investment
312.72
+154.19%
123.03
+215.45%
39.00
-78.38%
180.35
Financing Cash Flow
702.17
+36.52%
514.32
+459.83%
91.87
+777.89%
10.46
Cash Flow From Continuing Financing Activities
702.17
+36.52%
514.32
+459.83%
91.87
+777.89%
10.46
Net Common Stock Issuance
690.99
+34.96%
512.00
+459.00%
91.59
+857.98%
9.56
Repurchase Of Capital Stock
—
—
—
—
Proceeds From Stock Option Exercised
13.27
+404.14%
2.63
+532.93%
0.42
-70.83%
1.43
Net Other Financing Charges
-2.09
-578.25%
-0.31
-124.82%
-0.14
+73.75%
-0.52
Changes In Cash
141.96
+5.88%
134.07
+581.09%
19.68
+125.34%
-77.69
Beginning Cash Position
215.79
+164.07%
81.72
+31.73%
62.03
-55.60%
139.72
End Cash Position
357.75
+65.79%
215.79
+164.07%
81.72
+31.73%
62.03
Free Cash Flow
-249.12
-89.08%
-131.76
-18.50%
-111.19
+40.06%
-185.49
Amortization Of Securities
-3.59
+28.30%
-5.01
-10759.57%
0.05
-95.31%
1.00
Common Stock Issuance
690.99
+34.96%
512.00
+459.00%
91.59
+857.98%
9.56
Issuance Of Capital Stock
690.99
+34.96%
512.00
+459.00%
91.59
+857.98%
9.56
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
Preferred Stock Payments
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category